This #NationalDNAday we celebrate the scientific advancements that detect subtle changes with significant impacts. The EsoGuard test uses next generation sequencing, interrogating hundreds to thousands of genes at one time—making precancer detection possible. #EsophagealCancerAwarenessMonth
Lucid Diagnostics
Medical Equipment Manufacturing
New York, NY 6,210 followers
Lucid Diagnostics is an esophageal cancer prevention medical diagnostics company. Nasdaq: LUCD
About us
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing.
- Website
-
http://www.LucidDx.com
External link for Lucid Diagnostics
- Industry
- Medical Equipment Manufacturing
- Company size
- 51-200 employees
- Headquarters
- New York, NY
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
Get directions
one grand central place
Suite 4600
New York, NY 10165 , US
Employees at Lucid Diagnostics
-
Jim Fricchione
ESOPHAGEAL CANCER IS PREVENTABLE
-
Joe Erfort
-
Suman Verma
Chief Scientific Officer (CSO), Lucid Diagnostics (Nasdaq: LUCD), VP of Molecular Diagnostics, PAVmed Inc. (Nasdaq: PAVM)
-
Michael Parks
Global Communications Executive | Investor Relations and Public Affairs Leader | Issues Management Advisor
Updates
-
Did you know that nausea after eating, difficulty swallowing, loss of enamel and tooth decay can all be signs of gastroesophageal reflux disease? Chronic #GERD can lead to serious complications over time and can even lead to esophageal cancer. Don't ignore your symptoms, talk to your doctor about the EsoGuard test and #CheckYourFoodTube #EsophagealCancerAwarenessMonth
-
-
Highlights from #LabWeek2024 Our lab team's work is central to our focus on #cancerprevention. Together they leverage the power of #NGS to detect genetic changes that indicate the presence of disease. We celebrate their dedication, expertise, and relentless commitment to making an impact on #esophagealcancer. A special thanks to our partners who sponsored #LabWeek celebrations—Coast to Coast Business Equipment, Thermo Fisher Scientific, Mettler-Toledo Rainin, MACHEREY-NAGEL, USA Scientific, and Quartzy
-
-
-
-
-
+1
-
-
We are proud to support the #StepstoSaveLives 5k and Esophageal Cancer Action Network's mission of putting an end to Esophageal Cancer. How to join: 👉 Register at https://lnkd.in/g2z5cjZD 📧 Donate and share the link for others to donate to a great cause 🏃♀️April 21-28 — grab a friend and go for a walk, jog, or run! Your participation 🔥 GENERATES AWARENESS that heartburn can lead to cancer 👩⚕️ ENCOURAGES more people to talk to their doctors and get checked 👍 SUPPORTS the advocacy that has added more than $15 million in federal research funding for Esophageal Cancer #EsophagealCancerAwarenessMonth
-
-
Join us for the final day of the American College of Physicians Internal Medicine Meeting. Visit booth 549 to find out how you can offer your patients the in-office test that's changing the way esophageal precancer is detected. #NationalCancerPreventionMonth #EsoGuard
-
-
Visit booth 409 at #SAGES2024 to learn more about the non-endoscopic Barrett's esophagus screening tools featured in yesterday's presentations. #EarlyDetectionSavesLives #EsoGuard
-
-
About 20% of patients diagnosed with esophageal cancer survive five years after diagnosis. This makes #EarlyDetection critical for this highly lethal disease. EsoGuard is a DNA test that detects esophageal disease in the precancerous stage. Learn more about the test: EsoGuard.com #EsophagealCancerAwarenessMonth
-
-
Heading to the American College of Physicians Internal Medicine Meeting in Boston tomorrow? Visit our team at booth 549 to learn how you can provide your at-risk patients with the innovative test revolutionizing the detection of esophageal precancer. #EarlyDetectionSavesLives
-
-
See you at #SAGES this week! Join us at booth 409 to learn about the DNA test that's changing the way esophageal precancer is detected. #EarlyDetectionSavesLives #EsoGuard
-